Novartis OTC Stock Valuation

NVSEF
 Stock
  

USD 84.01  5.21  6.61%   

What is the value of Novartis today? Calculating the true value of any business is not as easy as it may seem. While the market cap of a public entity, such as Novartis, is its stock price multiplied by the total number of shares outstanding, calculating Novartis' enterprise value requires a different approach. It uses Novartis' balance sheet items such as long-term debt, the book value of the preferred stock, minority interest, and other important financials.
Novartis Ag Basl secures a last-minute Real Value of $70.01 per share. The latest price of the firm is $84.01. At this time, the firm appears to be overvalued. Our model forecasts the value of Novartis Ag Basl from analyzing the firm fundamentals such as Profit Margin of 45.63 %, return on equity of 43.06 %, and Current Valuation of 208.42 B as well as examining its technical indicators and Probability Of Bankruptcy. In general, we recommend purchasing undervalued stocks and exiting overvalued stocks since, at some point, asset prices and their ongoing real values will merge together.
  
Refresh
Novartis Valuation Module provides a unique way to ballpark how much the company is worth today. It is done using both, our quantitative analysis of the company fundamentals as well as its intrinsic market price estimation to project the real value. We also take into consideration other essential factors such as Novartis's management style, its c-level domain expertise and tenure, its overall leadership history as well as current capital structure, and future earnings potential.

Novartis Most Recent Valuation Data

Price Book
2.83
Enterprise Value
192.8 B
Enterprise Value Ebitda
5.85
Price Sales
3.63
Forward PE
12.67
Trailing PE
7.83
Enterprise Value Revenue
3.64
Overvalued
Today 84.01
Please note that Novartis' price fluctuation is very steady at this time. Calculation of the real value of Novartis Ag Basl is based on 3 months time horizon. Increasing Novartis' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Novartis Ag Basl is useful when determining the fair value of the Novartis otc stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Novartis. Since Novartis is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Novartis OTC Stock. However, Novartis' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
70.01
Real Value
92.41
Upside
Estimating the potential upside or downside of Novartis Ag Basl helps investors to forecast how Novartis otc stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Novartis more accurately as focusing exclusively on Novartis' fundamentals will not take into account other important factors:
Bollinger
Band Projection (param)
LowerMiddle BandUpper
75.6083.8892.16
Details
Hype
Prediction
LowEstimated ValueHigh
80.9584.0187.07
Details
Potential
Annual Dividend
LowIncome Per ShareHigh
2.032.202.38
Details

Novartis Valuation Ratios as Compared to Competition

Comparative valuation techniques use various fundamental indicators to help in determining Novartis's current stock value. Our valuation model uses many indicators to compare Novartis value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Novartis competition to find correlations between indicators driving Novartis's intrinsic value. More Info.
Novartis Ag Basl is rated below average in price to book category among related companies. It is regarded fourth in five year return category among related companies reporting about  0.99  of Five Year Return per Price to Book. The ratio of Price to Book to Five Year Return for Novartis Ag Basl is roughly  1.01 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Novartis by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Novartis' OTC Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Novartis' earnings, one of the primary drivers of an investment's value.
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Novartis' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Novartis and how it compares across the competition.

About Novartis Valuation

The equity valuation mechanism determines the current worth of Novartis Ag Basl on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Novartis Ag Basl. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Novartis Ag Basl based exclusively on its fundamental and basic technical indicators. By analyzing Novartis's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Novartis's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Novartis. We calculate exposure to Novartis's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Novartis's related companies.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. Novartis operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 110000 people.
Novartis' stock price is the clearest measure of market expectations about its performance. Without stock valuation, investors cannot independently discern whether Novartis' value is low or high relative to the company's performance and growth projections. Determining the market value of Novartis can be done in different ways, such as multiplying its stock price by its outstanding shares.
A single share of Novartis represents a small ownership stake in the entity. As a stockholder of Novartis, your percentage of company ownership is determined by dividing the number of shares you own by the total number of shares outstanding and then multiplying that amount by 100. Owning stock in a company generally confers both corporate voting rights and income from any dividends paid to the stock owner.

Novartis Dividends Analysis For Valuation

Please note that Novartis has scaled down on payment of dividends at this time.
There are various types of dividends Novartis can pay to its shareholders, and the actual value of the dividend is determined on a per-share basis. It is to be paid equally to all of Novartis shareholders on a specific date, known as the payable date. The cash dividend is the most common type of dividend payment - it is the payment of actual cash from Novartis Ag Basl directly to its shareholders. There are other types of dividends that companies can issue, such as stock dividends or asset dividends. When Novartis pays a dividend, it has no impact on its enterprise value. It does, however, lowers the Equity Value of Novartis by the value of the dividends paid out.

Novartis Valuation Growth Rates

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Novartis does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Quick Ratio0.92
Earnings Quarterly Growth7.90%
Revenue Growth0.90%
Payout Ratio31.35%
Enterprise Value To Ebitda11.60
Earnings Growth8.80%
Enterprise Value To Revenue3.93
Additionally, see Stocks Correlation. Note that the Novartis Ag Basl information on this page should be used as a complementary analysis to other Novartis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Shere Portfolio module to track or share privately all of your investments from the convenience of any device.

Complementary Tools for Novartis OTC Stock analysis

When running Novartis Ag Basl price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Is Novartis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novartis. If investors know Novartis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novartis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
0.088
Market Capitalization
192.6 B
Quarterly Revenue Growth YOY
0.009
Return On Assets
0.0651
Return On Equity
0.43
The market value of Novartis Ag Basl is measured differently than its book value, which is the value of Novartis that is recorded on the company's balance sheet. Investors also form their own opinion of Novartis' value that differs from its market value or its book value, called intrinsic value, which is Novartis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novartis' market value can be influenced by many factors that don't directly affect Novartis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novartis' value and its price as these two are different measures arrived at by different means. Investors typically determine Novartis value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novartis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.